JHVEPhoto Barron’s said this week that ResMed (NYSE:RMD) trades at a compelling valuation after the stock sold off last month in reaction to positive data for Eli Lilly’s (NYSE:LLY) GLP-1 therapy, tirzepatide, in obstructive sleep apnea, a condition targeted by the MedTech company. In late June, Lilly (LLY) said tirzepatide,Continue Reading
phongphan5922 Stock futures were trading higher in the pre-market hours on Monday, continuing the momentum from last week’s record highs, driven by excitement surrounding advancements in artificial intelligence. Here are some of Monday’s biggest stock movers: Biggest stock gainers RXO (NYSE:RXO) shares surged 15% after announcing the acquisition of CoyoteContinue Reading
jetcityimage/iStock Editorial via Getty Images Respiratory device makers ResMed (NYSE:RMD), and Philips (NYSE:PHG) traded lower on Friday after Eli Lilly (NYSE:LLY) said an FDA decision on a potential label expansion for its weight loss therapy tirzepatide against obstructive sleep apnea (OSA) is expected later this year. The announcement hurt theContinue Reading
